300 related articles for article (PubMed ID: 15583796)
1. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
2. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
5. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
6. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
7. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
8. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
9. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
12. [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].
Zhang XM; Liang Y; Dong Y; Zhang Y; Wang Y; Meng YT; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):135-41. PubMed ID: 22353917
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
[TBL] [Abstract][Full Text] [Related]
15. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
16. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
Haley SL; Malhotra RK; Qiu S; Eltorky ME
Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
[TBL] [Abstract][Full Text] [Related]
17. [Detection of mutation and protein expression of PTEN gene in endometrial carcinoma].
Xu B; Yao Q; Dai SZ
Ai Zheng; 2004 Jan; 23(1):69-73. PubMed ID: 14720379
[TBL] [Abstract][Full Text] [Related]
18. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome.
Peiró G; Lohse P; Mayr D; Diebold J
Am J Clin Pathol; 2003 Jul; 120(1):78-85. PubMed ID: 12866376
[TBL] [Abstract][Full Text] [Related]
20. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]